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Abstract
Background: Directly observed therapy (DOT) is a widely recommended and promoted strategy to manage
tuberculosis (TB), however, there is still disagreement about the role of DOT in TB control and the impact it has on
reducing the acquisition and transmission of drug resistant TB. This study compares the portion of drug resistant
genotype clusters, representing recent transmission, within and between communities implementing programs
differing only in their directly observed therapy (DOT) practices.
Methods: Genotype clusters were defined as 2 or more patient members with matching IS6110 restriction
fragment length polymorphism (RFLP) and spoligotype patterns from all culture-positive tuberculosis cases
diagnosed between January 1, 1995 and December 31, 2001. Logistic regression was used to compute maximum-
likelihood estimates of odds ratios (ORs) and 95% confidence intervals (CIs) comparing cluster members with and
without drug resistant isolates. In the universal DOT county, all patients received doses under direct observation of
health department staff; whereas in selective DOT county, the majority of received patients doses under direct
observation of health department staff, while some were able to self-administer doses.
Results: Isolates from 1,706 persons collected during 1,721 episodes of tuberculosis were genotyped. Cluster
members from the selective DOT county were more than twice as likely than cluster members from the universal
DOT county to have at least one isolate resistant to isoniazid, rifampin, and/or ethambutol (OR = 2.3, 95% CI: 1.7,
3.1). Selective DOT county isolates were nearly 5 times more likely than universal DOT county isolates to belong to
clusters with at least 2 resistant isolates having identical resistance patterns (OR = 4.7, 95% CI: 2.9, 7.6).
Conclusions: Universal DOT for tuberculosis is associated with a decrease in the acquisition and transmission of
resistant tuberculosis.
Background
Worldwide tuberculosis transmission continues despite
intensive control efforts and availability of highly effec-
tive, relatively inexpensive treatment regimens [1-3].
There are multiple reasons for the continued threat.
The time commitment for successful treatment of tuber-
culosis is longer than required for most acute medical
conditions [4,5]. Additional tuberculosis transmission
and the development of drug resistance can result when
tuberculosis treatment fails due to noncompliance [6].
Treatment noncompliance is difficult to predict and
identify prior to treatment failure [7-13]. A widely
recommended and promoted strategy attempting to
manage the situations leading to noncompliance is com-
monly referred to as directly observed therapy (DOT)
[14-16]. Nonetheless, there is still disagreement about
the role of DOT in tuberculosis control [17-19].
The skepticism surrounding DOT results from a lack
of a compelling scientific rationale supporting its effec-
tiveness. The rationale for DOT is based on treatment
outcomes in adherent patients in research settings;
clinical experiences of treatment failure related to non-
compliance; and DOT studies using a variety of designs,
methodologies, and definitions [1-5,18,20-22]. There are
practical impediments to completing well-designed stu-
dies on DOT efficacy; perhaps chief among these is an
ethical issue. An essential component of the protection
of human subjects in clinical trials is subjects’ ability to
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any medium, provided the original work is properly cited.withdraw from a study at any time with no loss of privi-
leges or rights [23]. Unlike most illnesses evaluated
through randomized trials, tuberculosis is a public
health problem that affects others in the community
through respiratory transmission. As a result, labora-
tories and physicians in some areas are legally mandated
to report the identity of persons with tuberculosis to
health authorities [24]. To prevent tuberculosis trans-
mission, persons with tuberculosis who are treatment-
noncompliant can face loss of personal liberty and com-
pletion of therapy can be a condition to regain liberty
[24-26]. Randomization to a treatment strategy where
study therapy, if not taken, can result in treatment being
legally mandated by public health authorities is proble-
matic [23]. This lack of randomized trials has resulted
in a lack of consensus on the program components that
are essential for a tuberculosis treatment policy to be
d e f i n e da sD O T .A sar e s u l t ,s t u d i e so fD O Th a v e
included different combinations of incentives and
enablers, tracing of defaulters, legal sanctions, patient-
centered approaches, staff motivation, supervision, and
funding [18,20-22]. Thus the efficacy of DOT remains
controversial at the same time it is widely recommended
[14,17-19].
The DOT policy for tuberculosis patients in Texas is a
comprehensive program that includes medical services
related to TB and delivery of medication to a patient-
chosen location at no cost to the patient. For patients
who default or decline therapy there is a legal frame-
work and dedicated facilities for inpatient hospital isola-
tion, (i.e., quarantine), until therapy is completed. The
two counties compared in this study are located in
urban north central Texas and had an incidence of 10.4
to 8.2 cases per 100,000 population (County A 1995,
2001) and 8.8 to 6.5 cases per 100,000 population
(County B 1995, 2001). The tuberculosis control pro-
grams of the two counties contain the same elements.
Both programs are managed by the local county health
departments, funded through the same formula to pro-
vide services to tuberculosis patients, under the same
contract standards, and overseen by the Texas Depart-
ment of State Health Services. Full microbiological
laboratory services, including susceptibility testing, are
equally available for each patient and use the same stan-
dards. First- and second-line anti-tubercular medications
are provided from the same central state-managed phar-
macy. Treatment decisions in both counties are made
by clinicians who follow Centers for Disease Control
and Prevention (CDC)/American Thoracic Society treat-
ment guidelines and have also participated in CDC
sponsored research in tuberculosis control. The princi-
pal management difference between these counties is
that they utilized different DOT strategies prior to and
during the time of this study. One county had provided
DOT to the majority of patients since 1986 while the
remainder received traditional self-administered therapy
(selective DOT); this is standard practice in most of the
US. There were no rigid criteria for managing a patient
with DOT. General criteria for DOT management
included: clinician judgment that the patient would ben-
efit from DOT, a prolonged period of smear or culture
positivity, and irregular attendance at scheduled visits.
The other county provided DOT to all persons sus-
pected of having or proven to have tuberculosis within
the county (universal DOT) during the same time per-
iod. If DOT is not more effective for managing tubercu-
losis than is self-supervision of therapy, then acquisition
and transmission of drug resistant strains should be
similar in both counties. A molecular epidemiologic
analysis of tuberculosis isolates representing transmis-
sion and drug susceptibilities is reported here.
Methods
As part of their participation in the National Tuberculo-
sis Genotyping and Surveillance Network sponsored by
CDC [27,28], the Texas Department of State Health Ser-
vices and the University of North Texas Health Science
Center at Fort Worth conducted a community-based
cohort study including two urban north Texas counties.
The University of Texas Health Science Center at San
Antonio (UTHSC-SA) laboratory served as the reference
genotyping laboratory for M. tuberculosis complex iso-
lates collected from each tuberculosis patient residing in
the counties from January 1, 1995 to December 31,
2001. The IS6110 restriction fragment length poly-
morphism (RFLP) fingerprint patterns of isolates were
submitted to the CDC and assigned a National Finger-
print Pattern [28].
Drug susceptibility testing
Drug susceptibility testing of the M. tuberculosis com-
plex isolates was performed with the rapid BACTEC
460TB radiometric system (Becton Dickinson, Paramus,
N.J.). The anti-tuberculosis drugs and concentrations
tested by the BACTEC 460TB system were as follows:
isoniazid (INH), 0.4 mcg/ml; rifampin (RIF), 2.0 mcg/ml;
and ethambutol (EMB), 2.5 mcg/ml [29]. Resistance to
any of the anti-tuberculosis agents was confirmed by the
Middlebrook 7H10 agar proportion method. The anti-
tuberculosis drugs and concentrations tested by the agar
proportion method were as follows: INH, 1.0 mcg/ml;
RIF, 1.0 mcg/ml; and EMB, 5.0 mcg/ml. Drug suscept-
ibilities reported were those obtained from the initial
isolate available and represent initial resistance. Initial
resistance in this study is a combination of primary
resistance in persons without prior treatment and
acquired resistance in persons who have been previously
treated.
Moonan et al. BMC Public Health 2011, 11:19
http://www.biomedcentral.com/1471-2458/11/19
Page 2 of 8Cluster definitions
Molecular characterization of M. tuberculosis, can help
elucidate transmission dynamics in communities.
IS6110-RFLP and spoligotype analyses were conducted
on all M. tuberculosis isolates as previously described
[30]. Genotype clusters are thought to represent recent
transmission [27-30]. Clusters were defined as groups of
two or more isolates having an identical spoligotype and
IS6110 RFLP pattern, allowing for the presence, absence
or shifting of no more than one band. Because we were
interested in both initial drug resistance and the direct
transmission of a drug-resistant strain, subsequent geno-
type clusters were further categorized as: (a) having no
drug resistant isolates from any cluster members, (b)
“resistant clusters” having at least one isolate resistant to
INH, RIF, or EMB from any cluster members; or (c)
“two-isolate resistant clusters” having at least two mem-
bers with isolates resistant to INH, RIF or EMB.
Data analysis
Texas State statute requires laboratories to report to the
health authority persons with cultures positive for M.
tuberculosis. Similarly clinicians are required to report
persons suspected or known to have tuberculosis. Data
from local health department tuberculosis databases
from each county was merged with a database of IS6110
RFLP fingerprint patterns from UTHSC-SA laboratory.
The merge was done by name, date of birth, and tuber-
culosis episode number. To maximize the number of
one-to-one matches between the databases, extensive
efforts were made to correct inconsistencies and inac-
curacies in both databases, such as name misspellings
and incorrect dates of birth. Isolates that could not be
matched were excluded from the study.
Demographic and clinical data was obtained for local
Health Department records. Due to incomplete coding,
a substantial proportion of records had missing foreign-
born (8%) and/or HIV status (13%). Original medical
records of a sample of subjects with missing data were
referenced to determine whether or not these data were
actually missing or left uncoded; based on this process,
it was determined that uncoded foreign-born and HIV
status variables had actual values of “no” and were
therefore coded as such in the merged database. Treat-
ment defaulters were defined as patients who were
reported as being lost.
Differences in age were tested using t-tests. All other
variables were categorical and were tested using Fisher’s
exact tests or chi square goodness-of-fit tests for com-
parisons to population distributions. Logistic regression
was used to compute maximum-likelihood estimates of
odds ratios (ORs) and 95% confidence intervals (CIs),
using both uni- and multivariable models. All isolates
were treated as independent units of analysis, although a
small percentage of patients (0.8%) had multiple isolates
in the database due to recurrent tuberculosis episodes
separated by at least one year and occurring between
1995 and 2001. All tests were two-sided with an alpha
of 0.05.
Treatment outcome data and the method of therapeu-
tic treatment (e.g. directly observed therapy vs. self-
administered therapy) were collected as part of routinely
reported variables to the CDC, U.S. National Tuberculo-
sis Surveillance System. Comparisons of proportions for
these data include all reportable cases for the study per-
iod, not just culture-positive cases with valid genotype
results.
The institutional review boards of the Centers for Dis-
ease Control and Prevention, the University of North
Texas Health Science Center at Fort Worth, and the
UTHSC-SA have approved this investigation.
Results
From January 1, 1995 to December 31, 2001, there were
2,106 culture confirmed cases of M. tuberculosis in the
two counties [31]. Of these, 1,721 viable clinical isolates
from 1,706 (81%) patients were available to the reference
genotyping laboratory for molecular analysis. Persons
excluded from analysis because there was no viable clin-
ical isolate of M. tuberculosis did not differ statistically
from those with viable isolates by age (P = 0.44), gender
(P = 0.56), or race (P = 0.70). One thousand twenty four
(60%) patients genotyped met the criteria for molecular
clustering. These patients were categorized into 148
clusters varying from 2 to 138 patients per group.
Twenty-six (1.5%) of the isolates had an identical low
copy RFLP pattern but did not have spoligotyping
conducted and were included as non-clustered isolates
(Figure 1).
Foreign birth and gender of tuberculosis patients did
not vary by county(data not shown). While age distribu-
tions of the general populations of these two counties
were the same (8% for those under 5 yrs, 20% for 5 - 17
yrs, 64% for 18 - 64 yrs, and 8% for those over 65 yrs.;
Table 1), the mean age at diagnosis was younger in the
selective DOT county; this difference was largely due to
the age distribution of clustered patients (40.4 ± 15.3
years in selective DOT vs 43.4 ± 15.9 years in universal
DOT among clustered patients, P = 0.004). Race/ethni-
city distributions of the general populations of these
counties were not similar, with the selective DOT
county having a more racially diverse population than
t h eu n i v e r s a lD O Tc o u n t y .A ss h o w ni nT a b l e1i nt h e
selective DOT county disproportionally affected blacks
and Asians were over-represented and non-Hispanic
whites were underrepresented compared to the general
population. In the universal DOT county, blacks, Hispa-
nics, and Asians were overrepresented and whites were
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higher percentage of tuberculosis patients with HIV co-
infection than the universal DOT county (15% [n = 183]
vs. 11% [n = 58], P = 0.03), with this difference was
greatest among clustered patients (19% [n = 135] vs.
13% [n = 39], P < 0.0001); the prevalence of HIV in the
general populations of the two counties is unknown.
Forty-one percent of patients reported with tuberculosis
(i.e., culture-confirmed and clinical cases) in the selec-
tive DOT county received DOT therapy versus 97% in
the universal DOT county. The selective DOT county
had a higher percentage of treatment defaulters (i.e., lost
to follow-up) than the universal DOT county (7.9% [n =
134] vs. 2.9% [n = 22]; p < 0.001). The selective DOT
county had a lower percentage of patients completing
treatment than the universal DOT county (85.9% [n =
1,448] vs. 90.7% [n = 745]; p < 0.01). Recurrent TB was
not significantly different between counties.
Table 2 shows comparisons by county on isolate char-
acteristics. One hundred twenty (7%) of the isolates
were resistant to at least INH, RIF, or EMB. Adjusting
for age, race, and HIV status, antitubercular drug resis-
tance to INH, RIF and/or EMB in the initial isolate was
over 1.5 times as common in the selective than in the
universal DOT county (p = 0.049). Isolates belonging to
clusters containing at least one isolate resistant to INH,
RIF and/or EMB ("resistant” clusters) were more than
twice as likely to occur in the selective than in the
Figure 1 Study population.
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to clusters with at least two isolates with resistant mem-
bers having the identical resistance pattern ("two-isolate
resistant” clusters) were over 4 times more likely in the
selective than in the universal DOT county (p < 0.0001).
When the analysis was confined to clusters with all
members exclusively in either county, isolates belonging
to resistant clusters remained significantly more com-
mon in the selective DOT county (OR = 3.8, 95%CI;
1.6, 8.8), as did isolates belonging to two-isolate resistant
clusters (OR = 5.1, 95%CI; 1.2, 21.7) (data not shown).
Frequency of relapse did not vary significantly by county
during the study period (1.0 vs 0.3%, p = 0.26). In the
selective DOT county 9 of 13 relapses were with the
same strain vs 1 of 2 relapses in the universal DOT
county (p = 1.00). Stratified by demographic factors that
significantly differed by county, INH, RIF and/or EMB
resistance appeared to be increasingly associated with
the selective DOT county with increasing age, and
seemed more associated with selective DOT among
blacks, Asians, and other ethnicities compared to whites
and Hispanics (Table 3). None of these potential effect
modifiers reached statistical significance. HIV status was
not an effect modifier.
Discussion
This is the first study to combine molecular genotyping
techniques and drug susceptibilities to demonstrate that
DOT for tuberculosis is associated with less initial drug
resistance and less transmission of drug resistant organ-
isms. Because the susceptibilities were taken from the
first available isolate, the initial resistance in this study
represents a combination of primary resistance and
acquired resistance in patients with previous treatment.
Isolates from genotype clusters containing members
with initial resistance were over 1.5 times as common in
Table 2 Number of isolates by isolate characteristics and type of county DOT program
Selective DOT county Universal DOT county
(n = 1207) (n = 514) Crude Adjusted
1
Isolate characteristic No. (%) No. (%) OR (95% CI) p-value OR (95% CI) p-value
EMB/INH/RIF resistant
2
No 1108 (92) 489 (95) 1.0 0.03 1.0 0.049
Yes 95 (8) 25 (5) 1.7 (1.1, 2.6) 1.6 (1.1, 2.6)
Unknown 4
Belongs to a resistant cluster
3
No 927 (77) 454 (88) 1.0 <0.0001 1.0 <0.0001
Yes 280 (23) 60 (12) 2.3 (1.7, 3.1) 2.1 (1.6, 2.9)
Belongs to a two-isolate resistant cluster
4
No 1024 (85) 495 (96) 1.0 <0.0001 1.0 <0.0001
Yes 183 (15) 19 (4) 4.7 (2.9, 7.6) 4.3 (2.6, 7.0)
1Adjusted for age, race, and HIV status.
2Resistant to EMB, INH, and/or RIF.
3Genotype-clustered with at least one isolate in cluster resistant to EMB, INH, and/or RIF.
4Genotype-clustered with at least two of the EMB-, INH- and/or RIF-resistant isolates having the same EMB-INH-RIF resistance pattern.
Table 1 Demographic characteristics by county
Selective DOT County Universal DOT County
TB Patients General Population p-value TB Patients General Population p-value
Demographic (n = 1,194) (n = 512)
Age (years) <5 2% 8% <0.0001 1% 8% <0.0001
5 - 17 3% 20% 2% 20%
18 - 64 85% 64% 84% 64%
≥65 10% 8% 12% 8%
Sex Male 66% 50% <0.0001 67% 49% <0.0001
Female 34% 50% 33% 51%
Race/ethnicity Black 42% 20% <0.0001 29% 13% <0.0001
Hispanic 29% 30% 24% 20%
White 17% 44% 31% 62%
Asian 11% 4% 15% 4%
Other 0% 2% 1% 1%
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DOT county. Universal DOT was also associated with
decreased transmission of drug resistant strains. Isolates
from genotype clusters having 2 or more members with
matching drug resistance profiles were over 4 times as
common in the selective DOT county as in the universal
DOT county. These findings remained significant when
the cluster definition was restricted from all clusters to
clusters whose members were within only one county.
Since other program components in the counties are
the same, this association is additional evidence that the
acquisition and transmission of resistant tuberculosis is
reduced by DOT.
Historically, it has been unclear whether or not DOT
reduces tuberculosis transmission. It is generally
accepted that most transmission of tuberculosis occurs
prior to diagnosis and treatment [32,33]. DOT could
reduce tuberculosis transmission by ensuring that conta-
gious patients become noninfectious as rapidly as is pos-
sible from treatment. If DOT is more effective, then
tuberculosis relapse with additional transmission could
be reduced.
T h e r ei sl a r g ev a r i a b i l i t yi nt h em e t h o d o l o g yo fD O T
programs throughout the world, as the essential compo-
nents for DOT strategy success have not been systema-
tically established through randomized trials. The World
Health Organization (WHO) defines five essential ele-
ments for Directly Observed Therapy Short-course
(DOTS) strategy: political commitment to control tuber-
culosis; microscopy services to identify tuberculosis;
uninterrupted good quality drug supplies; surveillance
and monitoring systems; and use of highly efficacious
regimes with direct observation of treatment for at least
the initial two months [15]. T h e s ec r i t e r i aa r es u f f i -
ciently broad that a person hospitalized for the initial
2 months of treatment with all subsequent therapy
being self-administered meets the definition of DOTS
strategy. Confusion can result when observation of ther-
apy is unnecessary for using DOT strategy. This lack
of standardization has resulted in studies being non-
comparable.
In one previously published study, DOT was defined
as therapy requiring economically impoverished ill per-
sons without transportation to come to a clinic during
working hours five times weekly for 8-12 weeks and
then thrice weekly until cured [18]. This study used a
maximally restrictive definition of DOT referred to
by one author as “supervised swallowing” and found
both self-supervised and DOT strategies to be equally
ineffective [17,18]. Over 40% of patients in both the self-
supervised therapy and the DOT arm failed to complete
therapy [17,18]. Another study defined DOT as the daily
delivery of medications to the patient at home for
2 months with subsequent self-supervised therapy to
cure. This study included a penalty of loss of monetary
bond if the patient defaulted on treatment. This more
comprehensive DOT program achieved cure rates of 85%
[34]. In much of the US, programs that strive to make
tuberculosis treatment maximally accessible and include
observation of therapy have been called DOT programs
[35]. Essential components of these DOT programs are
considered to include supplying therapy at no cost to the
patient at a location of the patient’s preference, combined
with adherence enhancing incentives and enablers and
quarantine of the noncompliant [21,27]. Some have called
this a strategy of making treatment easier to take than
Table 3 Differences in EMB/INH/RIF resistance by age, race, and HIV status, by county DOT program type1
Selective DOT county Universal DOT county
(n = 1207) (n = 514) Interaction
Stratifying factor No. Resistant (%) No. Resistant (%) OR (95% CI) p-value p-value
2
Age (yrs) 0.06
<30 28 (9) 8 (7) 1.3 (0.5, 2.9) 0.58
30 - 59 59 (8) 15 (5) 1.7 (0.9, 3.1) 0.08
60+ 8 (5) 2 (2) 2.1 (0.4, 10.2) 0.36
Race 0.11
Black 41 (8) 6 (4) 2.1 (0.9, 5.1) 0.09
Hispanic 20 (6) 10 (8) 0.7 (0.3, 1.5) 0.34
White 8 (4) 3 (2) 1.4 (0.3, 5.6) 0.65
Asian/other 26 (18) 6 (8) 2.8 (1.1, 7.1) 0.03
HIV status 0.52
Negative 74 (7) 20 (4) 1.6 (1.0, 2.7) 0.07
Positive 21 (11) 5 (8) 1.2 (0.4, 3.6) 0.68
1Separate analyses were done for each level of each stratifying factor; e.g., among patients aged <30, 28 (9%) patients from selective DOT and 8 (7%) from
universal DOT were resistant, with an OR of 1.3 associating increased resistance with selective DOT. Analyses were adjusted for age, race, and/or HIV status, as
appropriate, depending on the stratification factor.
2Interaction between DOT program and the stratifying factor.
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in a sustained reduction in relapse and both initial and
acquired anti-tubercular drug resistance [21,22]. In our
study the components of the tuberculosis programs were
the same in both counties. While the current study does
not demonstrate the essential components of a DOT pro-
gram, our data do demonstrate that universal DOT is
associated with a significantly improved treatment out-
come. Importantly, this DOT effect was independent of
medication supply, incentives and enablers, laboratory
services, funding, tracing and legal sanctions of defaulters,
and program supervision.
There are only a few drugs and regimens of proven
effectiveness in tuberculosis treatment. Drug-resistant
tuberculosis is therefore a major threat to public health.
If drug-resistant tuberculosis becomes widely spread,
the ability to control tuberculosis through medical ther-
a p yw i l lb es e r i o u s l yc o m p r o m i s e d .N o to n l ya r e
patients infected with strains resistant to multiple drugs
less likely to be cured, but the treatment is more toxic
and expensive than treatment of patients with suscepti-
ble organisms [5,37-39]. The emergence and transmis-
sion of drug-resistant M. tuberculosis into a population
can be related to a variety of program-, health provider-
and patient-related factors [38,39]. Patients’ noncompli-
ance to prescribed treatment is the most important
patient-related factor contributing to the development
of drug resistance [9,10,12,39]. Noncompliance cannot
be reliably predicted but is considered to be reduced in
programs that manage patients with DOT, thus result-
ing in less drug resistance [21,22]. Our study supports
this concept and preventing the development and
transmission of drug-resistant organisms by DOT is, at
present, the best strategy for dealing with resistant
tuberculosis.
Previous tuberculosis studies combining molecular
genotyping and epidemiologyh a v ed e m o n s t r a t e dt h a t
clustering represents disease due to recent transmission.
In this study clustering was greater in younger patients,
males, non-Hispanic blacks, patients born in the United
States, and patients with HIV co-infection, all factors
previously associated with clustering and recent trans-
mission [40]. We observed significant differences in age
and HIV co-infection between clustered isolates identi-
fied between the two counties; namely, among patients
with clustered isolates, t h o s ei nt h es e l e c t i v eD O T
county were significantly younger and more likely to be
HIV co-infected. A potential explanation is that DOT
optimizes treatment response and results in the shortest
possible period of contagion after diagnosis; therefore
less tuberculosis transmission involving younger
and HIV infected persons in the universal DOT county.
It must be noted that differences in rates of HIV infec-
tion observed between the two counties may reflect
differences in rates in the general populations, which
were unknown.
The principal limitation of this study was that treat-
ment by universal or selective DOT was not randomized
or controlled and we are therefore unable to say with
complete assurance that the associations identified are a
result of DOT. Potential confounders include demo-
graphic and income differences between the counties
which may have affected transmission (i.e., overcrowd-
ing, poverty). Successful tuberculosis control programs
are multifaceted and include all measures related to
aggressively identifying and treating patients with tuber-
culosis and latent tuberculosis infection. However, drug
resistance occurring within tuberculosis chemotherapy
programs is created only by monotherapy [41]. We
believe that the difference in DOT strategy is the only
difference between the two counties that can explain
the reduced acquisition and transmission of resistant
tuberculosis in the universal DOT county. While we
genotyped >80% of the culture-positive cases, these non-
genotyped cases are a potential source of misclassifica-
tion. Moreover, as the two counties are adjacent it is
conceivable that more resistant tuberculosis spread from
the universal DOT county to the selective DOT county,
indeed 692 patients were members of clusters that
spanned both counties. However, we believe this is unli-
kely, as resistance associations were the same in clusters
exclusive to each county as clusters that were geographi-
cally distributed across both counties.
Conclusions
These data suggest resistance is less likely to develop
and be transmitted when persons with tuberculosis are
managed with universal DOT as compared to selective
DOT. This provides additional support for recommend-
ing management of patients with universal DOT as the
best strategy for preventing the development and trans-
mission of drug-resistant tuberculosis. For optimal con-
trol of tuberculosis it will be necessary to define which
DOT program components are essential to achieve this
outcome.
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